Menu

Report Library

All Reports
Datamonitor Healthcare Oncology: Tumor Lysis Syndrome (TLS) Market Spotlight

November 24, 2022

Tumor lysis syndrome (TLS) comprises a group of metabolic disturbances that result from either chemotherapy or spontaneously induced tumor cell death. The release of intracellular components, including nucleic acids, electrolytes, and proteins, into the systemic circulation is triggered by tumor cytotoxicity. This may result in the development of metabolic abnormalities such as hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia. Clinically, this can lead to effects on multiple organs such as cardiac arrhythmias, seizures, and acute kidney injury. 

This Datamonitor Healthcare report contains a Market Spotlight module.

Indications Covered: Tumor Lysis Syndrome (TLS)
Back to the top Back to the top